The anti-tumor immunoresponses by unreplicable recombinant vaccinia virus expressing HPV16 L1,L2,and E7 proteins
- VernacularTitle:表达HPV16 L1、L2和E7蛋白的非复制重组痘苗病毒诱发的抗肿瘤免疫反应
- Author:
Jiangtao FAN
;
Xinqiu CHEN
;
Hui ZHANG
- Publication Type:Journal Article
- Keywords:
Human papillomavirus;
Vaccinia;
Vaccine;
Immune reaction
- From:
Chinese Journal of Immunology
1986;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the anti-tumor immune responses of nureplicable recombinant vaccinia virus-based vaccine expressing HPV16 L1 and L2E7 proteins.Methods:The anti-tumor effects of the vaccine were observed using mouse models of prophylactic,therapeutic and tumor excision.The cell-mediated immunity induced by the vaccine was assessed by enzyme-linked immunospot (ELISPOT) and cytotoxic T lymphocyte (CTL) assay.Results:The vaccine could protect 60% and 50% mice from the challenge of HPV16-positive tumor cells in prophylactic and therapeutic mouse model,respectively.It could protect from recurrence of the tumor in 70% mice of the excision model.The differences among the groups were significant.Strongly specific cell-mediated immunity was found using ELISPOT and CTL assay.Conclusion:The ideal anti-tumor immune responses can be induced by NTVJL1/L2E7 vaccine in mice and it can be considered to be one candidate vaccine of cervical cancer.
